Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
ClinicalTrials.gov · NCT07513168 · Registry updated: 2026-04-06
- Condition / research focus
- Obesity; Weight Reduction; Cardiometabolic Risk Factors
- Sponsor
- Asian Institute Of Medical Sciences
- Countries with listed sites
- Pakistan
- Registry dates and results
- Start: 2025-08-01. Completion: 2026-12-01 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg) (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Asian Institute of Medical Sciences
Hyderābād, Sindh, Pakistan
Site recruitment: Recruiting